Clinical evaluation of the GSD NovaPrime® SARS-CoV-2 RTq-PCR assay

Marie Tré-Hardy, Sébastien Piteüs, Ingrid Beukinga, Laurent Blairon

    Research output: Contribution to journalArticlepeer-review


    Faced with the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), high-throughput respiratory tests are in high demand. We evaluated the clinical performance of the GSD NovaPrime® SARS-CoV-2 RTq-PCR assay, a new assay that detects 2 specific RNA sequences of the nucleocapsid (N) gene. It was assessed using 99 nasopharyngeal samples and compared in parallel with the Allplex® assay. Among those samples, 72 and 27 were included in the positive (PPA) and negative (NPA) percent agreement analyses, respectively. In case of discordance, samples were reanalyzed with another amplification technique, the Aptima® SARS-CoV-2 assay. Cross-reactivity, including specimens positive for another respiratory virus and collected before the COVID-19 outbreak, was also evaluated (n = 32). Based on the patients’ clinical history, the Ct (cycle threshold) values obtained, and the results of the Aptima® assay, the clinical performances were deemed satisfactory, with the PPA reaching a minimum percentage of 87.5% and the NPA reaching 100%. No cross-reactivity with other respiratory viruses was observed.

    Original languageEnglish
    Article number115718
    JournalDiagnostic Microbiology and Infectious Disease
    Issue number3
    Publication statusPublished - Jul 2022


    • Clinical evaluation
    • COVID-19
    • RT-qPCR
    • SARS-CoV-2


    Dive into the research topics of 'Clinical evaluation of the GSD NovaPrime® SARS-CoV-2 RTq-PCR assay'. Together they form a unique fingerprint.

    Cite this